Skip to search formSkip to main contentSkip to account menu

LCI699

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ImidazolesPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Efficacy and safety of LCI 699 for hypertension : a meta-analysis of randomized controlled trials and systematic review
296 Abstract. – OBJECTIVE: This study reviews the available data from randomized controlled trials on efficacy and safety of… 
2015
2015
Effects of osilodrostat (LCI699) on cytochrome P450 enzymes in healthy volunteers indicates a low drug-drug interaction potential
2015
2015
Phase III, multicentre, double-blind, randomised withdrawal study of osilodrostat (LCI699) in patients with Cushing's disease: a study design
2014
2014
Medical management of functioning pituitary adenoma: an update.
The treatment of functioning pituitary adenoma (FPA) must achieve endocrinological remission as well as tumor size reduction. The… 
2012
2012
Letter by Keidar and Gamliel-Lazarovich
inwhich the authors tested the effect of a novel aldosterone synthaseinhibitor, LCI699, for treatment of primary hypertension. An… 
2010
2010
HORMONAL EFFECTS OF THE NEW DIRECT ALDOSTERONE SYNTHASE INHIBITOR, LCI699, IN PATIENTS WITH PRIMARY ALDOSTERONISM: 5C.06
Objective: Aldosterone synthase inhibition with LCI699 is a new therapeutic option aimed at decreasing hormone concentrations in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)